Prostate cancer
Conditions
Interventions
Control group:Take rezvilutamide orally 1 day in advance before GnRH agonist (Goserelin).
Experimental group:Interval of 1 hour between rezvilutamide and GnRH agonist (Goserelin).
Sponsors
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age > 18 years, and within 1 month of initial diagnosis of prostate adenocarcinoma by pathology. 2. Prior to initiation of treatment, a bone scan, chest and abdominal CT, and pelvic MRI were performed, which were sufficient for TNM staging, with at least one distant metastasis (extra-pelvic lymph node metastasis, bone metastasis, or visceral metastasis). 3. PSA > 2 ng/ml at initiation of therapy, and serum testosterone level greater than 150 ng/dl.
Exclusion criteria
Exclusion criteria: 1. Combinations of severe cardio-cerebral and pulmonary systemic diseases that interfere with the implementation of the treatment program. 2. Prostate adenocarcinoma non-major component. 3. Clinical situations in which indwelling urinary catheters, punctures, and acute infections significantly affect PSA levels within 1 week. 4. Patients who cannot be followed up regularly during treatment for reasons such as poor adherence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostate-specific antigen;Luteinizing hormone;Testosterone;Imaging changes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in clinical symptoms; | — |
Countries
China
Contacts
Public ContactChunguang Yang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed